Osiris Therapeutics, Inc. (OSIR)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 9.14 / 19.30
Exchange NASDAQ
Div & Yield N.A. (N.A)
Osiris Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results Conference Call

Osiris Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2012, on Wednesday, March 6, 2013.

Osiris Therapeutics Receives Title Of European Orphan Drug Designation For Prochymal®

Osiris Therapeutics Receives Title Of European Orphan Drug Designation For Prochymal®

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading company focused on developing and marketing stem cell products to treat serious medical conditions, announced today the successful conclusion of a patent challenge...

10 Biotech Stocks With A History Of Beating Earning Expectations

10 Biotech Stocks With A History Of Beating Earning Expectations

The fourth quarter earnings season has just begun. Some companies manage to consistently surprise the market with positive earnings reports. [...]

5 Under-$10 Stocks Due to Surge

5 Under-$10 Stocks Due to Surge

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

The Next Big Thing in Biotech: Worst CEO Candidates

The Next Big Thing in Biotech: Worst CEO Candidates

Adam Feuerstein, senior columnist for TheStreet, is assembling candidates for the Worst Biotech CEO of 2012 award.

Osiris Therapeutics To Present At The 24th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics To Present At The 24th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...

Osiris Therapeutics Reports Third Quarter 2012 Financial Results

Osiris Therapeutics Reports Third Quarter 2012 Financial Results

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...

Biotech Stock Mailbag: More Amarin, MannKind, Orexigen

Biotech Stock Mailbag: More Amarin, MannKind, Orexigen

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call

Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the third quarter ended September 30, 2012, on Monday, November 5, 2012.

Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer

Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today it has promoted Lode Debrabandere, Ph.

Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris

Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Swissmedic Invokes Rapid Authorization Procedures For Prochymal Review

Swissmedic Invokes Rapid Authorization Procedures For Prochymal Review

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today that it has been notified by Swissmedic, the Swiss agency responsible for the evaluation of drugs, that Prochymal® (remestemcel-L) will be evaluated under...

Osiris Therapeutics Regains Worldwide Rights To Prochymal And Chondrogen

Osiris Therapeutics Regains Worldwide Rights To Prochymal And Chondrogen

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced the conclusion of its collaboration with Genzyme, a Sanofi company.

Osiris Therapeutics Announces Change In Its Board Of Directors

Osiris Therapeutics Announces Change In Its Board Of Directors

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today the passing of one of its Board Members, Gregory H.

Osiris Therapeutics To Present At 2012 UBS Global Life Sciences Conference

Osiris Therapeutics To Present At 2012 UBS Global Life Sciences Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...

Biotech Stock Mailbag: Mela, Osiris, Talon

Biotech Stock Mailbag: Mela, Osiris, Talon

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Osiris Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Osiris Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Osiris Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Osiris Therapeutics Reports Second Quarter 2012 Financial Results

Osiris Therapeutics Reports Second Quarter 2012 Financial Results

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...

Osiris Therapeutics Announces Second Quarter 2012 Financial Results Conference Call

Osiris Therapeutics Announces Second Quarter 2012 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the second quarter ended June 30, 2012, on Monday, July 30, 2012.

A Biotech Short-Seller Responds to Critics

A Biotech Short-Seller Responds to Critics

Rigorously debate the short thesis but stop attacking the messenger, he says.

Osiris Selected By BARDA To Submit Proposal For The Use Of Grafix® In Mass Casualty Thermal Burn Injuries

Osiris Selected By BARDA To Submit Proposal For The Use Of Grafix® In Mass Casualty Thermal Burn Injuries

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today that the company has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to submit a full proposal for a Broad Agency ...

Osiris Therapeutics To Present At The Seventh Annual JMP Securities Healthcare Conference

Osiris Therapeutics To Present At The Seventh Annual JMP Securities Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company, announced today that C.

7 High-Volume Stocks With Relative Strength

7 High-Volume Stocks With Relative Strength

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Update: How to Tell When A Drug Company Fibs About Clinical Trial Results

Update: How to Tell When A Drug Company Fibs About Clinical Trial Results

Osiris claims a stem-cell study in heart attack patients was positive but with key data missing, who can really tell?

How to Tell When A Drug Company Fibs About Clinical Trial Results

How to Tell When A Drug Company Fibs About Clinical Trial Results

Osiris claims a stem-cell study in heart attack patients was positive but with key data missing, who can really tell?

Prochymal Significantly Reduces Hypertrophy, Arrhythmia And Progression To Heart Failure In Patients Suffering A Heart Attack

Prochymal Significantly Reduces Hypertrophy, Arrhythmia And Progression To Heart Failure In Patients Suffering A Heart Attack

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today interim one-year results from its groundbreaking clinical trial evaluating Prochymal® ( remestemcel-L) for the treatment of patients experiencing...

Osiris Bolsters Its Stem Cell Intellectual Property Estate

Osiris Bolsters Its Stem Cell Intellectual Property Estate

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the expansion of its intellectual property protection around Prochymal® (remestemcel-L).

Osiris Stock Falls On Unusually High Volume (OSIR)

Osiris Stock Falls On Unusually High Volume (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) is trading at unusually high volume Wednesday with 1.4 million shares changing hands. It is currently at 4.2 times its average daily volume and trading down $2.41 (-17.4%).

Osiris Rises On Unusually High Volume (OSIR)

Osiris Rises On Unusually High Volume (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) is trading at unusually high volume Friday with 1.1 million shares changing hands. It is currently at 4.2 times its average daily volume and trading up 56 cents (+4.8%).